Question 1

What are the potential side effects of MK-4002?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) clinical trial (NCT04184050). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) clinical trial (NCT04184050). Contact the study team or your healthcare provider for specific answers.

Question 3

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) clinical trial (NCT04184050). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) clinical trial (NCT04184050). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific eligibility requirements I need to meet?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) clinical trial (NCT04184050). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) clinical trial (NCT04184050). Contact the study team or your healthcare provider for specific answers.

What this study is about